deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT04794972

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-039 in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Conditions Recurrent Glioma Solid Tumor
Interventions GNC-039
Updated 13 times since 2021 Last updated: Sep 26, 2025 Started: Apr 14, 2021 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Recurrent Glioma and Solid Tumor and is currently actively recruiting participants. Sichuan Baili Pharmaceutical Co., Ltd. leads this study, which shows 13 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Jan 2023 · 16 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Oct 2025 · 10 months · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

13 versions recorded

  1. Oct 2025 — Present [monthly]

    Recruiting PHASE1

  2. Dec 2024 — Oct 2025 [monthly]

    Recruiting PHASE1

  3. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

▶ Show 8 earlier versions

  1. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE1

  2. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  3. Apr 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  4. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1

  5. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1

  6. Sep 2021 — Jan 2023 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  7. May 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1

  8. Apr 2021 — May 2021 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sichuan Baili Pharmaceutical Co., Ltd.
  • SystImmune Inc.
Data source: Sichuan Baili Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations